NDAORALTABLET, EXTENDED RELEASEPriority Review
Approved
May 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
Priority Review
MS CONTIN (morphine sulfate) by Purdue Pharma is mu-opioid receptor, although it can bind to other opioid receptors at higher doses. Approved for chronic pain, pain, cancer pain. First approved in 1987.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MS CONTIN is an extended-release oral morphine sulfate tablet approved in 1987 for chronic pain management across multiple indications including cancer pain, osteoarthritis, postoperative pain, and opioid use disorder. It works as a full mu-opioid receptor agonist with no ceiling effect for analgesia, providing sustained pain relief through CNS opioid receptor activation. The drug's long-acting formulation enables dosing convenience while managing pain through titration to patient tolerance and efficacy.
$0.001BPart D
LOE ApproachingDeclining
MS CONTIN faces LOE approaching with minimal Part D spending ($1M, 1,166 claims in 2023), indicating significant market contraction and likely reduction in commercial team size.
Mechanism of Action
mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may…
Indications (3)
Worked on MS CONTIN at Purdue Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.